Thursday, 28 January 2010

Nilatac




Nilatac may be available in the countries listed below.


Ingredient matches for Nilatac



Clotiazepam

Clotiazepam is reported as an ingredient of Nilatac in the following countries:


  • Japan

International Drug Name Search

Posted by at No comments:
Labels:

Sunday, 24 January 2010

Paracetamol Pensa




Paracetamol Pensa may be available in the countries listed below.


Ingredient matches for Paracetamol Pensa



Paracetamol

Paracetamol is reported as an ingredient of Paracetamol Pensa in the following countries:


  • Spain

International Drug Name Search

Posted by at No comments:
Labels:

Fluspiral




Fluspiral may be available in the countries listed below.


Ingredient matches for Fluspiral



Fluticasone

Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Fluspiral in the following countries:


  • Italy

International Drug Name Search

Posted by at No comments:
Labels:

Saturday, 23 January 2010

Zoloft


Zoloft is a brand name of sertraline, approved by the FDA in the following formulation(s):


ZOLOFT (sertraline hydrochloride - concentrate; oral)



  • Manufacturer: PFIZER

    Approval date: December 7, 1999

    Strength(s): EQ 20MG BASE/ML [RLD][AA]

ZOLOFT (sertraline hydrochloride - tablet; oral)



  • Manufacturer: PFIZER

    Approval date: December 30, 1991

    Strength(s): EQ 100MG BASE [RLD][AB], EQ 50MG BASE [AB]


  • Manufacturer: PFIZER

    Approval date: March 6, 1996

    Strength(s): EQ 25MG BASE [AB]

Has a generic version of Zoloft been approved?


A generic version of Zoloft has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zoloft and have been approved by the FDA:


sertraline hydrochloride concentrate; oral



  • Manufacturer: AUROBINDO PHARMA

    Approval date: October 31, 2008

    Strength(s): EQ 20MG BASE/ML [AA]


  • Manufacturer: RANBAXY

    Approval date: February 5, 2007

    Strength(s): EQ 20MG BASE/ML [AA]

sertraline hydrochloride tablet; oral



  • Manufacturer: APOTEX INC

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: AUSTARPHARMA LLC

    Approval date: March 4, 2009

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: DR REDDYS LABS LTD

    Approval date: April 30, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: HIKMA PHARMS

    Approval date: August 10, 2009

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: INVAGEN PHARMS

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: LUPIN

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: MATRIX LABS LTD

    Approval date: January 31, 2008

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: March 20, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: RANBAXY

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: SUN PHARM INDS (IN)

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: TEVA

    Approval date: August 11, 2006

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: TORRENT PHARMS

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: WATSON LABS

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: WOCKHARDT

    Approval date: January 8, 2008

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: ZYDUS PHARMS USA

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zoloft. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Sertraline polymorph
    Patent 5,248,699
    Issued: September 28, 1993
    Inventor(s): Sysko; Robert J. & Allen; Douglas J. M.
    Assignee(s): Pfizer Inc.
    This invention relates to a novel crystalline polymorphic form of sertraline hydrochloride, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4 -tetrahydro-N-methyl-1-naphthalenamine hydrochloride, and to a method for preparing it.
    Patent expiration dates:

    • August 13, 2012


    • February 13, 2013
      ✓ 
      Pediatric exclusivity




  • Sertraline oral concentrate
    Patent 6,727,283
    Issued: April 27, 2004
    Inventor(s): Nancy J.; Harper & Gautam R.; Ranade & Willard M.; Welch
    Assignee(s): Pfizer Inc.
    The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
    Patent expiration dates:

    • October 11, 2019
      ✓ 
      Patent use: TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
      ✓ 
      Drug product


    • April 11, 2020
      ✓ 
      Pediatric exclusivity




  • Sertraline oral concentrate
    Patent 7,067,555
    Issued: June 27, 2006
    Inventor(s): Harper; Nancy J. & Ranade; Gautam R. & Welch; Willard M.
    Assignee(s): Pfizer Inc
    The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
    Patent expiration dates:

    • November 10, 2019
      ✓ 
      Drug product


    • May 10, 2020
      ✓ 
      Pediatric exclusivity



See also...

  • Zoloft Consumer Information (Drugs.com)
  • Zoloft Consumer Information (Wolters Kluwer)
  • Zoloft Concentrate Consumer Information (Wolters Kluwer)
  • Zoloft Consumer Information (Cerner Multum)
  • Zoloft Advanced Consumer Information (Micromedex)
  • Zoloft AHFS DI Monographs (ASHP)
  • Sertraline Consumer Information (Drugs.com)
  • Sertraline Consumer Information (Wolters Kluwer)
  • Sertraline Concentrate Consumer Information (Wolters Kluwer)
  • Sertraline Consumer Information (Cerner Multum)
  • Sertraline Advanced Consumer Information (Micromedex)
  • Sertraline Hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Tuesday, 19 January 2010

NasenSpray-ratiopharm Erwachsene




NasenSpray-ratiopharm Erwachsene may be available in the countries listed below.


Ingredient matches for NasenSpray-ratiopharm Erwachsene



Xylometazoline

Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of NasenSpray-ratiopharm Erwachsene in the following countries:


  • Germany

International Drug Name Search

Posted by at No comments:
Labels:

Saturday, 9 January 2010

Cysteine




In some countries, this medicine may only be approved for veterinary use.


In the US, Cysteine (cysteine systemic) is a member of the drug class intravenous nutritional products.

US matches:

  • Cysteine Hydrochloride

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0000052-90-4

Chemical Formula

C3-H7-N-O2-S

Molecular Weight

121

Therapeutic Categories

Amino acid

Cataract treatment

Chemical Name

L-Cysteine

Foreign Names

  • Cysteinum (Latin)
  • Cystein (German)
  • Cystéine (French)
  • Cisteina (Spanish)

Generic Names

  • Cystéine (OS: DCF)
  • Cys (IS)
  • L-Cystéine (IS: DCF vieille)
  • Cystein (PH: DAB 2003)

Brand Names

  • Cisteína
    ALM, Peru


  • Crystfan (Cysteine and Ascorbic Acid)
    Nisshin Seiyaku - Yamagata, Japan


  • Cystina
    Galpharma, Tunisia


  • Ecolan
    Sanwa Kagaku, Japan


  • Hythiol
    Hisamitsu, Japan


  • L-Cysteine Domesco
    Domesco, Vietnam


  • Parematil (Cysteine and Chlorphenamine (veterinary use))
    Omega Pharma France, France

International Drug Name Search

Glossary

DCFDénomination Commune Française
ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.
Posted by at No comments:
Labels:

Wednesday, 6 January 2010

Orofer




Orofer may be available in the countries listed below.


Ingredient matches for Orofer



Iron Polymaltose

Iron Polymaltose is reported as an ingredient of Orofer in the following countries:


  • Myanmar

International Drug Name Search

Posted by at No comments:
Labels:

Tuesday, 5 January 2010

Nasenspray elac




Nasenspray elac may be available in the countries listed below.


Ingredient matches for Nasenspray elac



Xylometazoline

Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of Nasenspray elac in the following countries:


  • Germany

International Drug Name Search

Posted by at No comments:
Labels:

Monday, 4 January 2010

Ropinirole Hydrochloride




Ropinirole Hydrochloride may be available in the countries listed below.


Ingredient matches for Ropinirole Hydrochloride



Ropinirole

Ropinirole Hydrochloride (BANM, USAN) is known as Ropinirole in the US.

International Drug Name Search

Glossary

BANMBritish Approved Name (Modified)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.
Posted by at No comments:
Labels:

Sunday, 3 January 2010

Florate




Florate may be available in the countries listed below.


Ingredient matches for Florate



Fluorometholone

Fluorometholone 17-acetate (a derivative of Fluorometholone) is reported as an ingredient of Florate in the following countries:


  • Brazil

International Drug Name Search

Posted by at No comments:
Labels:

Saturday, 2 January 2010

Zopax




Zopax may be available in the countries listed below.


Ingredient matches for Zopax



Alprazolam

Alprazolam is reported as an ingredient of Zopax in the following countries:


  • South Africa

International Drug Name Search

Posted by at No comments:
Labels:
Subscribe to: Comments (Atom)